Bladder Cancer and Genetic Mutations

@article{Zhang2015BladderCA,
  title={Bladder Cancer and Genetic Mutations},
  author={Xiaoying Zhang and Yangde Zhang},
  journal={Cell Biochemistry and Biophysics},
  year={2015},
  volume={73},
  pages={65-69}
}
The most common type of urinary bladder cancer is called as transitional cell carcinoma. The major risk factors for bladder cancer are environmental, tobacco smoking, exposure to toxic industrial chemicals and gases, bladder inflammation due to microbial and parasitic infections, as well as some adverse side-effects of medications. The genetic mutations in some chromosomal genes, such as FGFR3, RB1, HRAS, TP53, TSC1, and others, occur which form tumors in the urinary bladder. These genes play… 
Implications of targeted next-generation sequencing for bladder cancer: report of four cases
TLDR
Investigation of mutational BRCA changes in bladder cancer is a promising marker for better treatment strategy and further studies are encouraged on a large cohort of bladder cancer patients to confirm the findings.
Vascular Endothelial Growth Factor Polymorphism in Bladder Cancer: A Review
TLDR
The present study aims to raise knowledge about the role of VEGF polymorphisms on risk of bladder cancer by evaluating the relationship between V EGF polymorphism and the risk of urinary tract cancers.
Prognostic factors of non-muscle invasive bladder cancer: a study based on next-generation sequencing
TLDR
BCG instillation significantly reduced the rate of recurrence compared with epirubicin in this population of bladder cancer patients, and correlations between DDR genes alterations and high tumor mutation burden were demonstrated.
Assessment of molecular mechanisms and potential biomarkers in bladder urothelial carcinoma
TLDR
The protein products of six cell cycle genes, which were upregulated in bladder urothelial carcinoma, showed significant association with patient survival and proposed potential prognostic biomarkers for this cancer.
Correlation of BRCA2 gene mutation and prognosis as well as variant genes in invasive urothelial carcinoma of the bladder.
TLDR
It is suggested that the BRCA2 gene mutation is a good prognostic factor and can be used as a gene to predict the prognosis in the bladder cancer patients.
Prevalence of bladder cancer in Costello syndrome: New insights to drive clinical decision‐making
TLDR
It is document that individuals with CS aged 10 years and older have high prevalence of bladder lesions (premalignant/malignant), highlighting the importance of personalized screening protocols.
Single nucleotide polymorphism mutation related genes in bladder cancer for the treatment of patients: a study based on the TCGA database
TLDR
Findings provide important bioinformatics and theoretical basis for understanding the pathogenesis of BLCA and exploring the detailed mechanisms of mutant genes in the disease.
Bioinformatics Analysis to Screen the Key Prognostic Genes in Tumor Microenvironment of Bladder Cancer
TLDR
A series of TME-related genes that assess the prognosis of BLCA are identified and the interaction between TME and tumor prognosis is explored to guide clinical individualized treatment.
Targeting Major Signaling Pathways of Bladder Cancer with Phytochemicals: A Review
TLDR
The major signaling pathways implicated in bladder cancer, including PI3K/AKT/mTOR, Ras/Raf/MEK/MAPK, NF-κB, Wnt/β‐catenin, Notch, Hedgehog, Hippo, JAK/STAT, and TGF-β are reviewed as well as major cellular receptors central to cancer pathophysiology, including EGFR, Her2, FGFR, and VEGF.
Bioinformatics Analysis to Screen the Key Prognostic Genes in Tumor Microenvironment of Bladder Cancer
TLDR
A series of TME-related genes that assess the prognosis of BLCA are identified and the interaction between TME and tumor prognosis is explored to guide clinical individualized treatment.
...
...

References

SHOWING 1-10 OF 22 REFERENCES
Identification of p53 gene mutations in bladder cancers and urine samples.
TLDR
The p53 mutations are the first genetic alterations demonstrated to occur in a high proportion of primary invasive bladder cancers, and Detection of such mutations ex vivo has clinical implications for monitoring individuals whose tumor cells are shed extracorporeally.
Bladder cancer.
  • H. Ozen
  • Biology, Medicine
    Current opinion in oncology
  • 1998
TLDR
It is postulated that the loss of the function of wild-type p53 allows cells with DNA damage to proceed through the cell cycle, replicating genetic errors, and thus decreased pRb expression in bladder cancer correlates with increased mitotic index.
p53 mutations in bladder cancer: evidence for exogenous versus endogenous risk factors.
TLDR
Estimates for p53 subtypes were imprecise but support in vitro evidence that some CpG G:C-A:T transitions may be caused by smoking and other environmental mutagens.
Concurrent Alterations in TERT, KDM6A, and the BRCA Pathway in Bladder Cancer
TLDR
This study is the first to identify frequent BAP1 and BRCA pathway alterations in bladder cancer, show TERT promoter alterations are independent of other bladder cancer gene alterations, and show KDM6A loss is a driver of the bladder cancer phenotype.
Molecular biomarkers in urothelial carcinoma of the bladder: are we there yet?
  • G. Netto
  • Medicine, Biology
    Nature Reviews Urology
  • 2012
TLDR
The need for new treatment options that can improve upon the modest outcomes currently associated with muscle-invasive bladder cancer is evident, and validated prognostic molecular biomarkers that can help clinicians to identify patients in need of early, aggressive management are lacking.
p53 mutations in human bladder cancer: Genotypic versus phenotypic patterns
TLDR
The sensitivity and specificity to detect p53 mutations using clinical material was assessed for the following assays: immunohistochemistry, restriction‐fragment‐length polymorphism, single‐strand‐conformation polymorphisms, and sequencing.
Atlas of Genetics and Cytogenetics in Oncology and Haematology
TLDR
WWTR1 (also called TAZ in publications) is a WW domaing-containing transcriptional coactivator, which was first identified as a 14-3-3 binding protein that is involved in mesenchymal stem cell differentiation as well as tumorigenesis.
American Association for Cancer Research
TLDR
A major session at this annual gathering of the cancer researchers from around the globe dealt with the current state of immunotherapy for cancer, which continued the trend of impressive biosafety of both cell- and antibody-based vaccines.
Identification of p 53 gene mutations in bladder cancers and urine samples
  • 1991
...
...